BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Carisma Therapeutics Inc. (Nasdaq - CARM), Guaranty Bancshares, Inc. (NYSE - GNTY), MRC Global Inc. (NYSE - MRC), Turnstone Biologics Corp. (Nasdaq - TSBX)

BALA CYNWYD, Pa., June 27, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.

Carisma Therapeutics Inc. (Nasdaq - CARM)

Under the terms of the Merger Agreement, Carisma will be acquired by OrthoCellix, Inc. (OrthoCellix), a wholly-owned subsidiary of Ocugen, Inc. (Nasdaq - OCGN). Upon the closing of the proposed transactions, existing Carisma stockholders are expected to own approximately 10% of the combined company. The investigation concerns whether the Carisma Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including the dilution to the Company’s shareholders in the combined entity.

Additional information can be found at https://www.brodskysmith.com/cases/carisma-therapeutics-inc-nasdaq-carm/.

Guaranty Bancshares, Inc. (NYSE - GNTY)

Under the terms of the agreement, Guaranty will be acquired by Glacier Bancorp, Inc. (“Glacier”) (NYSE - GBCI). Guaranty shareholders are to receive 1.0000 share of Glacier stock for each Guaranty share. Based on the closing price of $41.58 for Glacier shares on June 23, 2025, the transaction would result in aggregate consideration of $476.2 million and value of $41.58 per Guaranty share. The investigation concerns whether the Guaranty Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal provides fair value to the Company’s shareholders.

Additional information can be found at https://www.brodskysmith.com/cases/guaranty-bancshares-inc-nyse-gnty/.

MRC Global Inc. (NYSE - MRC)

Under the terms of the Merger Agreement, MRC will be acquired by DNOW Inc. (“DNOW”) (NYSE - DNOW). MRC shareholders will receive 0.9489 shares of DNOW common stock for each share of MRC common stock. Upon completion of the transaction, DNOW and MRC shareholders will respectively own approximately 56.5% and approximately 43.5% of the combined company on a fully diluted basis. The investigation concerns whether the MRC Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including the dilution to the Company’s shareholders in the combined entity.

Additional information can be found at https://www.brodskysmith.com/cases/mrc-global-inc-nyse-mrc/.

Turnstone Biologics Corp. (Nasdaq - TSBX)

Under the terms of the agreement, Turnstone will be acquired by XOMA Royalty Corporation (“XOMA Royalty”) (Nasdaq - XOMA) for $0.34 in cash per share of Turnstone common stock plus one non-transferable contingent value right (“CVR”). The investigation concerns whether the Turnstone Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company’s shareholders.

Additional information can be found at https://www.brodskysmith.com/cases/turnstone-biologics-corp-nasdaq-tsbx/.

Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.